A GLP-1 drug extended lifespan by about 12% in older mice — with healthier mitochondria among the changes, in lab models

GLP-1 drugs such as semaglutide are prescribed for diabetes and weight management. A study published in Nature (Feng, Chen and colleagues, 2026) asked a different question: started late in life, can semaglutide slow aging itself? Twenty-month-old female C57BL/6 mice — roughly analogous to humans in their early sixties — received semaglutide either for three months (to measure aging phenotypes) or for the rest of their lives (to measure lifespan). Fresh coverage of the study ran October 13-16, 2026, including an NIH-funded University of California mouse-study report highlighted in this week's longevity scan.

What changed in the treated mice?

Median lifespan rose from 742 to 834 days — about 12%. Treated mice performed better on balance, coordination, grip strength, endurance, exploration and memory-related behavior. At the molecular level, treatment attenuated hallmarks of aging: inflammation, genomic instability and DNA damage, cellular senescence, mitochondrial dysfunction, loss of proteostasis and impaired hippocampal neurogenesis — with shifts across nutrient-sensing regulators including IGF-1, NAD+ and sirtuin pathways. In plain terms, the mitochondria in treated animals functioned better alongside nearly every other aging system measured.

Was it the drug — or just eating less?

That is the study's central ambiguity, and the researchers tested it directly: a separate group was calorie-restricted by about 25%, matching the reduced intake on semaglutide. Calorie-restricted mice also lived longer, and for many muscle and mobility measures the two groups performed about the same. But the semaglutide group did better on cognition and maze performance and managed blood sugar better than calorie restriction alone — leading the authors to argue the benefit is more than eating less, while the precise split between reduced intake and direct GLP-1 receptor effects remains unresolved.

What does this mean for people taking GLP-1 drugs?

Directly, nothing yet. No GLP-1 drug is approved for aging or lifespan, no human trial has tested lifespan, and the study's corresponding author has stated there is no indication similar results could be immediately achieved in humans. The one human aging-related signal — an exploratory, post hoc epigenetic-clock analysis in a small HIV-associated lipodystrophy trial — was not pre-specified and is not generalizable. This story belongs in the promising-animal-results file: a strong, well-controlled mouse finding with an honest confounder, awaiting any human evidence at all.

Where the evidence stands

• Established: Semaglutide is an approved GLP-1 receptor agonist for diabetes and weight management; it reduces food intake, and calorie restriction itself extends lifespan in mice.
• Preliminary: In 20-month-old female mice (Nature, 2026), lifelong semaglutide extended median lifespan about 12% (834 vs 742 days) and improved strength, cognition and multiple aging hallmarks including mitochondrial dysfunction — with some advantages over matched calorie restriction.
• Absent: Any human evidence that semaglutide or other GLP-1 drugs slow biological aging or extend lifespan, and any established longevity dose in people.